Most attention Bristol-Myers Squibb Co. gets these days centers on its pacesetting immuno-oncology franchise, but the pharma's 17% sales growth reported July 28 stemmed as much from increased sales of Orencia and Eliquis, as well as a surprising uptick for its hepatitis C drug Daklinza (daclatasvir). Despite the consensus-beating quarterly revenue for the NS5A inhibitor, however, Bristol conceded that newer competition is likely to erode its HCV sales quickly.
The anti-PD-1 stalwart Opdivo (nivolumab) was Bristol's top-seller during the second quarter, the New York-based pharma reported during a July...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
